Company Analysis

Genelux Corporation (GNLX)

Nasdaq: GNLX · Pharmaceutical Preparations · Westlake Village, CA · filing with the SEC since 2003
Grade4.1
◀ Past 2.8● Present 3.3▶ Future 5.7
2 est.

Who runs Genelux Corporation

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Zindrick Thomas
President and CEO. First filing Jan 2023, latest Nov 5, 2026, 10 filings in all.
Officers reporting now
7
of 11 people with a filing in the last fifteen months
Directors reporting now
4
18 people on the record since 2023
Officerssales are open-market, Nov 5, 2025 to Nov 5, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Zindrick ThomasPresident and CEOJan 2023Nov 5, 20266 · $100,000
Cappello JosephChief Technical OfficerJan 2023Nov 5, 20266 · $0.00
Yu TonyChief Scientific OfficerJan 2023Nov 5, 20266 · $0.00
Pulisic MatthewChief Financial OfficerFeb 2025Jun 18, 2026none
Groen EricGeneral CounselJul 2025Jun 18, 2026none
Smalling RalphHead of RegulatoryJul 2023Jun 4, 20266 · $0.00
Litten JasonChief Medical OfficerJan 2026Jan 7, 2026none
Directorssales are open-market, Nov 5, 2025 to Nov 5, 2026
NameRoleFirst filingLatest filingSales, 12 months
Smither John WdirectorSep 2023Jul 2, 20261 · $0.00
Mirabelli MarydirectorJan 2023Jun 18, 2026none
Thomas JohndirectorJan 2023Jun 18, 20263 · $100,000
Tyree James LdirectorJan 2023Jun 18, 2026none
Earlier names on the record8, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton GNLX · research, not advice